ArticleAsian Pacific journal of cancer prevention : APJCP2024
Downregulation of lncRNA-MALAT1, Altered Immunohistochemical Expression of Cyclin D1 Protein and E-Cadherin Protein in Correlation to Meningioma Grades.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic Alterations in Meningiomas-A Review.Biomedicines · 2026Review
- Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMetastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is known to be upregulated in the tumors with ability to metastasize. In contrast, long non-coding Ribonuclei acid (lncRNA) MALAT1 was reported by some studies to be downregulated in meningioma cells. E-cadherin and Cyclin D1 are prognostic indicators and possible attractive targets for the treatment of recurring and aggressive meningioma. This study aimed to evaluate the expression level of lncRNA MALAT1, as well as Cyclin D1 and E-cadherin immunohistochemical expression in meningiomas (Grade 1 and 2) and their association with the clinicopathological parameters of the studied cases. MATERIAL AND
methodsQuantitative determination of relative expression levels of lncRNA-MALAT1 in 64 cases of meningioma to 5 controls of normal dura mater was performed, in addition to evaluation of E-cadherin and Cyclin D1 immunohistochemical expression. The results were tested for association with the clinicopathological parameters.
resultslncRNA-MALAT1 expression were downregulated in 49/64 of the cases of meningioma (76%) in comparison to control. There were significant association of expression of lncRNA-MALAT1 with grade, brain invasion and increased mitosis (p=0.007, 0.04, 0.006 respectively). There were also significant associations of strong E-cadherin and negative Cyclin D1 proteins expression with grade 1 (p = 0.02, 0.004), low mitosis (p=0.03, and 0.04) and brain invasion (p=0.04, 0.03) respectively. Additionally, a significant weak negative correlation between E-cadherin and Cyclin D1 expression was fond, yet no significant correlation between lncRNA MALAT1 expression and either of E-cadherin or Cyclin D1 expression could be achieved.
conclusionlncRNA MALAT1 is downregulated in meningiomas and associated with increased aggressiveness. Overexpressed cyclin D1 and decreased E-cadherin expression are also associated with high grade meningioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.